Your support fuels our research to #EndALS! Donate Now


TDI 208

Scientists at the ALS Therapy Development Institute are testing this small molecule in an attempt to address the oxidative stress observed in the cells of PALS.


Type: Small Molecule
Stage: Preclinical
Status: Active
Sponsor: ALS Therapy Development Institute

TDI Says:

This potential treatment was added to our pipeline in 2015 and is currently undergoing important experiments. These tests will help us better understand its pharmacokinetics and allow us to determine a prudent dosing strategy in efficacy testing.

Comment on this Topic

(All comments are moderated before they appear here.)